TheraNexus announced that it has received €3.6 million in its seed round of funding on November 17, 2014. The transaction included participation from new investors, Groupe Rhône-Alpes Création, Emergence Innovation 1, FCPR, a fund co-managed by Soridec SA and Sofimac Partners, Amorçage Technologique Investissement, a fund managed by an existing investor CEA Investissement SA, and Auriga Partners. Emmanuelle Coutanceau of Auriga Partners, Cécile Thébault of Sofimac Partners, Celia Hart of CEA Investissement, and Gwenaël Hamon of Rhône Alpes Création will join the board of supervisors of the company.

On November 17, 2014, TheraNexus closed the transaction.

Charles Gavoty of jones day acted as legal advisor.